JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Short-Term Bond ETF
BSV
|
+$5.57B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.73B |
| 3 |
AbbVie
ABBV
|
+$1.02B |
| 4 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$827M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$778M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.43B |
| 2 |
Amazon
AMZN
|
+$1.85B |
| 3 |
Cigna
CI
|
+$1.16B |
| 4 |
Microsoft
MSFT
|
+$1.08B |
| 5 |
Morgan Stanley
MS
|
+$1.07B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 28.67% |
| 2 | Technology | 15.47% |
| 3 | Financials | 11.13% |
| 4 | Healthcare | 9.58% |
| 5 | Consumer Discretionary | 9.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5576
WPP
WPP
$5.49B
| $58K | ﹤0.01% |
856
+195
| +30% | +$13.1K |
2013 Q2
33 quarters
|
|
|
HYRE
5577
DELISTED
HyreCar Inc. Common Stock
HYRE
| $58K | ﹤0.01% |
6,901
-85,676
| -93% | -$1.17M |
2021 Q2
1 quarter
|
|
|
KLDO
5578
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $58K | ﹤0.01% |
10,540
+992
| +10% | +$6.15K |
2019 Q1
10 quarters
|
|
|
BCYC
5579
Bicycle Therapeutics
BCYC
$272M
| $57K | ﹤0.01% |
1,365
-691
| -34% | -$24.2K |
2021 Q1
2 quarters
|
|
|
CIFRW
5580
DELISTED
Cipher Mining Warrant
CIFRW
| – | – |
0
| – | – |
2021 Q3
0 quarters
|
|
5581
VanEck Preferred Securities ex Financials ETF
PFXF
$2.35B
| $57K | ﹤0.01% |
2,680
+1,700
| +173% | +$36.5K |
2019 Q3
8 quarters
|
|
|
TCFC
5582
DELISTED
The Community Financial Corporation Common Stock
TCFC
| $57K | ﹤0.01% |
1,552
-907
| -37% | -$32.5K |
2017 Q4
15 quarters
|
|
|
MOTV.WS
5583
DELISTED
Motive Capital Corp Warrants, each whole warrant exercisable for one Class A ordinary share at an ex
MOTV.WS
| – | – |
0
| – | – |
2021 Q3
0 quarters
|
|
|
REV
5584
DELISTED
Revlon, Inc.
REV
| $57K | ﹤0.01% |
5,583
-5,313
| -49% | -$60K |
2017 Q3
16 quarters
|
|
5585
Invesco Taxable Municipal Bond ETF
BAB
$835M
| $56K | ﹤0.01% |
1,700
| – | – |
2020 Q2
5 quarters
|
|
5586
VanEck BDC Income ETF
BIZD
$1.45B
| $56K | ﹤0.01% |
3,250
-1,524
| -32% | -$26.1K |
2020 Q2
5 quarters
|
|
5587
Schwab Fundamental Emerging Markets Large Company Index ETF
FNDE
$10.5B
| $56K | ﹤0.01% |
1,752
+315
| +22% | +$10K |
2018 Q2
13 quarters
|
|
5588
Pan American Silver
PAAS
$19.2B
| $56K | ﹤0.01% |
2,400
-8,616
| -78% | -$225K |
2014 Q1
30 quarters
|
|
5589
PUT
Pacific Biosciences
PACB
$740M
| $56K | ﹤0.01% |
+2,200
| New | +$65.2K |
2021 Q3
0 quarters
|
|
5590
Protara Therapeutics
TARA
$164M
| $56K | ﹤0.01% |
8,040
+7,863
| +4,442% | +$61.3K |
2020 Q1
6 quarters
|
|
|
CSCI
5591
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
| $56K | ﹤0.01% |
746
-174
| -19% | -$12.4K |
2017 Q2
17 quarters
|
|
|
GSAQW
5592
DELISTED
Global Synergy Acquisition Corp. Warrant
GSAQW
| – | – |
0
| – | – |
2021 Q3
0 quarters
|
|
|
MBII
5593
DELISTED
Marrone Bio Innovations, Inc.
MBII
| $56K | ﹤0.01% |
62,487
+23,690
| +61% | +$28.5K |
2018 Q2
13 quarters
|
|
5594
Acumen Pharmaceuticals
ABOS
$155M
| $55K | ﹤0.01% |
+3,672
| New | +$61.1K |
2021 Q3
0 quarters
|
|
5595
Bain Capital Specialty
BCSF
$693M
| $55K | ﹤0.01% |
3,728
+282
| +8% | +$4.29K |
2019 Q2
9 quarters
|
|
5596
iShares MSCI Peru and Global Exposure ETF
EPU
$554M
| $55K | ﹤0.01% |
2,075
-1,660
| -44% | -$44.9K |
2018 Q1
14 quarters
|
|
5597
Goldman Sachs BDC
GSBD
$989M
| $55K | ﹤0.01% |
3,000
-5,916
| -66% | -$113K |
2017 Q1
18 quarters
|
|
5598
iShares Morningstar Multi-Asset Income ETF
IYLD
$124M
| $55K | ﹤0.01% |
2,301
+110
| +5% | +$2.67K |
2020 Q1
6 quarters
|
|
5599
Solid Biosciences
SLDB
$754M
| $55K | ﹤0.01% |
1,529
| – | – |
2018 Q1
14 quarters
|
|
|
TERN
5600
DELISTED
Terns Pharmaceuticals
TERN
| $55K | ﹤0.01% |
5,254
-6,165
| -54% | -$64K |
2021 Q1
2 quarters
|
|
Similar funds
JP Morgan Chase's Q3 2021 Portfolio in Review
As of Q3 2021, JP Morgan Chase held 7,104 positions worth $809B, down 3.5% from $838B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q3 2021 filing shows 647 new, 2,077 increased, 3,085 reduced and 500 closed positions. Its largest new stake was Toast: 2,760,295 shares worth $138M. The largest sale was Apple, an estimated $2.43B.
By sector, the portfolio is most concentrated in Miscellaneous at 29% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q3 2021 buy was Toast: 2,760,295 shares worth $138M.
- JP Morgan Chase added most to Vanguard Short-Term Bond ETF in Q3 2021, an estimated $5.57B increase.
- JP Morgan Chase's biggest Q3 2021 reduction was Apple, cutting an estimated $2.43B.
- JP Morgan Chase fully exited Weingarten Realty Investors in Q3 2021, selling an estimated $401M.
- JP Morgan Chase's ten largest holdings make up 16% of its $809B portfolio in Q3 2021.
- JP Morgan Chase opened 647 new positions and closed 500 in Q3 2021.
- JP Morgan Chase's portfolio value fell 3.5% quarter-over-quarter to $809B.
Based on JP Morgan Chase's 13F filing for Q3 2021, filed 12 Nov 2021.